EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response

Svenja Müller, Klaus Lieb, Fabian Streit, Swapnil Awasthi, Stefanie Wagner, Josef Frank, Marianne B Müller, André Tadic, Stefanie Heilmann-Heimbach, Per Hoffmann, Laven Mavarani, Börge Schmidt und 4 weitere

Journal of Affective Disorders · 2024-10 · 363 · 542-551

DOI: 10.1016/j.jad.2024.07.138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2024-10. Verfasst von Svenja Müller und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, G…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents, Multifactorial Inheritance. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Given the great interest in identifying reliable predictors of the response to antidepressant drugs, the present study investigated whether polygenic scores (PGS) for Major Depressive Disorder (MDD) and antidepressant treatment response (ADR) were related to the complex trait of antidepressant response in the Early Medication Change (EMC) cohort. METHODS: In this secondary analysis of the EMC trial (N = 889), 481 MDD patients were included and compared to controls from a population-based cohort. Patients were treated over eight weeks within a pre-defined treatment-algorithm. We investigated patients' genetic variation associated with MDD and ADR, using PGS and examined the association of PGS with treatment outcomes (early improvement, response, remission). Additionally, the influence of two cytochrome P450 drug-metabolizing enzymes (CYP2C19, CYP2D6) was determined. RESULTS: PGS for MDD was significantly associated with disorder status (NkR2 = 2.48 %, p < 1*10-12), with higher genetic burden in EMC patients compared to controls. The PGS for ADR did not explain remission status. The PGS for MDD and ADR were also not associated with treatment outcomes. In addition, there were no effects of common CYP450 gene variants on ADR. LIMITATIONS: The study was limited by variability in the outcome parameters due to differences in treatment and insufficient sample size in the used ADR genome-wide association study (GWAS). CONCLUSIONS: The present study confirms a polygenic contribution to MDD burden in the EMC patients. Larger GWAS with homogeneity in antidepressant treatments are needed to explore the genetic variation associated with ADR and realize the potential of PGS to contribute to specific response subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAntidepressive AgentsMultifactorial InheritanceHumansMaleFemaleAdultMiddle AgedTreatment OutcomeCytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19Cohort StudiesGenetic Variation

Stichwörter der Autor:innen

Antidepressant treatmentMajor depressive disorderPharmacogeneticsPolygenic scoresPredictionTreatment outcome

Substanzen

Antidepressive AgentsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19CYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), Partner site Mannheim/…
  • Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany.
  • Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
  • Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany; Translational Psychiatry, Department of Psychiatry and Psychotherapy & Focus Program Translational Neuroscience, University Medical…
  • Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany; Department of Psychiatry, Psychosomatics, and Psychotherapy, DR. FONTHEIM Mentale Gesundheit, Liebenburg, Germany.

Zitieren

APA

Müller, S., Lieb, K., Streit, F., Awasthi, S., Wagner, S., Frank, J., Müller, M. B., Tadic, A., Heilmann-Heimbach, S., Hoffmann, P., Mavarani, L., Schmidt, B., Rietschel, M., Witt, S. H., Zillich, L., & Engelmann, J. (2024). Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response. Journal of Affective Disorders, 363, 542-551. https://doi.org/10.1016/j.jad.2024.07.138

Vancouver

Müller S, Lieb K, Streit F, Awasthi S, Wagner S, Frank J, et al. Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response. Journal of Affective Disorders. 2024;363:542-551. doi:10.1016/j.jad.2024.07.138

BibTeX
@article{Mller2024,
  author = {Müller, Svenja and Lieb, Klaus and Streit, Fabian and Awasthi, Swapnil and Wagner, Stefanie and Frank, Josef and Müller, Marianne B and Tadic, André and Heilmann-Heimbach, Stefanie and Hoffmann, Per and Mavarani, Laven and Schmidt, Börge and Rietschel, Marcella and Witt, Stephanie H and Zillich, Lea and Engelmann, Jan},
  title = {Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response},
  journal = {Journal of Affective Disorders},
  year = {2024},
  volume = {363},
  pages = {542--551},
  doi = {10.1016/j.jad.2024.07.138}
}
Kostenlos starten →